Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy

BACKGROUND: As neoadjuvant chemotherapy (NAC) is increasingly used in triple-negative breast cancer (TNBC), we investigated the value of circulating tumor DNA (ctDNA) for patient monitoring prior, during, and after NAC, and circulating tumor cells (CTCs) for disease characterization at clinical prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortolan, E., Appierto, V., Silvestri, M., Miceli, R., Veneroni, S., Folli, S., Pruneri, G., Vingiani, A., Belfiore, A., Cappelletti, V., Vismara, M., Dell'Angelo, F., De Cecco, L., Bianchi, G.V., de Braud, F.G., Daidone, M.G., Di Cosimo, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010400/
https://www.ncbi.nlm.nih.gov/pubmed/33743331
http://dx.doi.org/10.1016/j.esmoop.2021.100086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010400/
https://www.ncbi.nlm.nih.gov/pubmed/33743331
http://dx.doi.org/10.1016/j.esmoop.2021.100086

Ejemplares similares